

POSTER PRESENTATION

Open Access

Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance

Douglas Palmer^{1*}, Geoff Guittard², Zulmarie Franco², Shashank Patel², Christopher A Klebanoff³, Madhusudhanan Sukumar³, Robert L Eil¹, David Clever³, Lakshmi Balagopalan², Rahul Roychoudhuri³, Larry Samelson², Nicholas Restifo²

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

Improving the functional avidity of effector T cells is critical in overcoming inhibitory factors within the tumor microenvironment and eliciting tumor regression.

Methods

We have found that Cish, a member of the Suppressor of Cytokine Signaling (SOCS) family, is induced by TCR stimulation in CD8⁺ T cells and inhibits their functional avidity against tumor.

Results

Genetic deletion of *Cish* in CD8⁺ T cells enhances their expansion, functional avidity and cytokine polyfunctionality, resulting in pronounced and durable regression of established tumors. Although Cish is commonly thought to block STAT5 activation, we found that the primary molecular basis of Cish suppression is through inhibition of TCR signaling. Cish physically interacts with the TCR intermediate PLCg1, targeting it for proteasomal degradation following TCR stimulation. Furthermore we extend these findings to patients PBL retrovirally transduced with tumor-specific TCRs and shorthairpin microRNAs targeting *CISH*.

Conclusions

These findings establish a novel targetable interaction that regulates the functional avidity of tumor-specific CD8⁺ T cells and can be manipulated to improve adoptive cancer immunotherapy.

Authors' details

¹NIH/NCI - Surgery Branch, Bethesda, MD, USA. ²NCI, Bethesda, MD, USA. ³Center for Cancer Research, NCI/NIH, Bethesda, MD, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P39

Cite this article as: Palmer et al.: Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P39.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹NIH/NCI - Surgery Branch, Bethesda, MD, USA
Full list of author information is available at the end of the article